Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus doses, ...

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

July 2, 2004 — Continuous subcutaneous insulin infusion (CSII) improved glycemic control in children and adolescents with type 1 diabetes better than did multiple daily injection (MDI) with glargine, ...

NORTH CHICAGO, Ill., Oct. 28, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa ...

- PRODUODOPA® (foslevodopa/foscarbidopa) is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 1 diabetes reported improved quality of life and glycemic control when using a continuous ...

SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- The global continuous subcutaneous insulin infusion market size is expected to reach USD 7.3 billion by 2027, registering a CAGR of10.3% over the forecast ...

Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. A ...

PHILADELPHIA — Continuous intracerebroventricular administration of an anaerobic dopamine formulation (A-dopamine) appears safe in patients with Parkinson's disease (PD) and may avoid complications ...

The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...

Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically planning ...